Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBIO Fortress Biotech	$1.83 +2.8%	$1.64	$1.33 ▼ $2.89	$54.11M	1.85	406,060 shs	195,438 shs
IPA ImmunoPrecise Antibodies	$0.53 -4.1%	$0.44	$0.27 ▼ $1.18	$24.44M	-0.05	2.11 million shs	346,759 shs
LGVN Longeveron	$1.34 -0.7%	$1.49	$0.77 ▼ $6.40	$20.00M	0.38	2.96 million shs	89,961 shs
VTVT vTv Therapeutics	$16.05 -9.6%	$19.26	$12.12 ▼ $27.50	$51.20M	0.77	23,384 shs	10,710 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBIO Fortress Biotech	+2.81%	+4.57%	+11.59%	+14.38%	-2.14%
IPA ImmunoPrecise Antibodies	-4.15%	+8.96%	+18.67%	+49.50%	-51.89%
LGVN Longeveron	-0.74%	0.00%	-23.43%	-11.26%	+21.82%
VTVT vTv Therapeutics	-9.63%	-22.65%	-28.84%	-11.15%	-42.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBIO Fortress Biotech	2.1393 of 5 stars	3.5	0.0	2.8	3.3	0.6
IPA ImmunoPrecise Antibodies	2.8706 of 5 stars	3.5	5.0	2.4	0.0	1.3
LGVN Longeveron	3.341 of 5 stars	3.6	5.0	2.1	1.7	1.3
VTVT vTv Therapeutics	2.1955 of 5 stars	3.5	5.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBIO Fortress Biotech	3.00	Buy	$21.00	1,047.54% Upside
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	649.06% Upside
LGVN Longeveron	3.25	Buy	$8.67	546.77% Upside
VTVT vTv Therapeutics	3.00	Buy	$35.50	121.18% Upside

Current Analyst Ratings Breakdown

Latest LGVN, FBIO, VTVT, and IPA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/9/2025	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
4/1/2025	IPA ImmunoPrecise Antibodies	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00 ➝ $3.00
3/31/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
3/21/2025	LGVN Longeveron	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/14/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/11/2025	FBIO Fortress Biotech	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $16.00
3/3/2025	LGVN Longeveron	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBIO Fortress Biotech	$57.78M	0.94	N/A	N/A	$0.10 per share	18.30
IPA ImmunoPrecise Antibodies	$24.00M	1.02	N/A	N/A	$0.93 per share	0.57
LGVN Longeveron	$2.23M	8.99	N/A	N/A	$2.68 per share	0.50
VTVT vTv Therapeutics	$17K	3,011.74	N/A	N/A	($9.27) per share	-1.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBIO Fortress Biotech	-$60.64M	-$2.23	N/A	N/A	N/A	-84.53%	N/A	-34.93%	8/12/2025 (Estimated)
IPA ImmunoPrecise Antibodies	-$20.13M	-$1.16	N/A	N/A	N/A	-114.50%	-73.74%	-42.68%	8/4/2025 (Estimated)
LGVN Longeveron	-$21.41M	-$6.28	N/A	N/A	N/A	-967.49%	-142.43%	-100.84%	N/A
VTVT vTv Therapeutics	-$20.25M	-$3.01	N/A	∞	N/A	N/A	-184.64%	-47.29%	8/14/2025 (Estimated)

Latest LGVN, FBIO, VTVT, and IPA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	VTVT vTv Therapeutics	-$0.73	-$0.77	-$0.04	-$0.77	N/A	N/A
3/31/2025	Q4 2024	FBIO Fortress Biotech	-$0.79	-$0.26	+$0.53	-$0.26	$16.30 million	$15.12 million
3/28/2025	Q3 2025	IPA ImmunoPrecise Antibodies	-$0.06	-$0.06	N/A	-$0.46	$6.59 million	$4.23 million
3/20/2025	Q4 2024	VTVT vTv Therapeutics	-$0.87	-$0.55	+$0.32	-$0.55	N/A	$0.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBIO Fortress Biotech	N/A	1.23	1.06
IPA ImmunoPrecise Antibodies	0.36	1.01	0.85
LGVN Longeveron	N/A	7.67	7.67
VTVT vTv Therapeutics	N/A	6.69	6.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBIO Fortress Biotech	96.51%
IPA ImmunoPrecise Antibodies	6.70%
LGVN Longeveron	10.01%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
FBIO Fortress Biotech	33.40%
IPA ImmunoPrecise Antibodies	6.83%
LGVN Longeveron	19.12%
VTVT vTv Therapeutics	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBIO Fortress Biotech	170	29.57 million	18.39 million	Optionable
IPA ImmunoPrecise Antibodies	80	45.77 million	28.94 million	Not Optionable
LGVN Longeveron	20	14.93 million	12.00 million	Not Optionable
VTVT vTv Therapeutics	9	3.19 million	3.15 million	Not Optionable

LGVN, FBIO, VTVT, and IPA Headlines

Recent News About These Companies

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average - Here's Why

May 26 at 5:14 AM | marketbeat.com

vTv resumes Phase III oral T1D drug study

May 21, 2025 | thepharmaletter.com

vTv Therapeutics Appoints Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer

May 19, 2025 | quiverquant.com

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Passes Above 50-Day Moving Average - Here's Why

May 18, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)

May 17, 2025 | theglobeandmail.com

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025 | globenewswire.com

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025 | globenewswire.com

vTv Therapeutics (VTVT) to Release Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Expands By 42.2%

May 2, 2025 | marketbeat.com

vTv Therapeutics Appoints Barry Brown as Interim CFO

April 11, 2025 | tipranks.com

vTv Therapeutics initiated with a Buy at H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation

April 9, 2025 | msn.com

vTv Therapeutics cleared to resume clinical trial of diabetes therapy

March 26, 2025 | ncbiotech.org

vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year

March 21, 2025 | markets.businessinsider.com

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 20, 2025 | globenewswire.com

vTv Therapeutics Inc.: vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

March 18, 2025 | finanznachrichten.de

Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics

March 18, 2025 | markets.businessinsider.com

vTv Therapeutics says FDA has lifted clinical hold on cadisegliatin program

March 17, 2025 | markets.businessinsider.com

vTv Therapeutics stock surges on FDA update

March 17, 2025 | au.investing.com

Vtv Therapeutics Shares Halted as FDA Clinical Hold on Diabetes Treatment Lifted

March 17, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN, FBIO, VTVT, and IPA Company Descriptions

Fortress Biotech NASDAQ:FBIO

$1.83 +0.05 (+2.81%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.83 0.00 (-0.05%)

As of 06:11 AM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

ImmunoPrecise Antibodies NASDAQ:IPA

$0.53 -0.02 (-4.15%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$0.54 +0.01 (+1.31%)

As of 05:04 AM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Longeveron NASDAQ:LGVN

$1.34 -0.01 (-0.74%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.37 +0.03 (+2.24%)

As of 04:05 AM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

vTv Therapeutics NASDAQ:VTVT

$16.05 -1.71 (-9.63%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$16.52 +0.47 (+2.96%)

As of 05/27/2025 04:05 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time